<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00096239</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000390237</org_study_id>
    <secondary_id>UCLA-0311057-01</secondary_id>
    <secondary_id>PFIZER-A3521003</secondary_id>
    <nct_id>NCT00096239</nct_id>
  </id_info>
  <brief_title>CP-547,632 in Treating Patients With Recurrent or Persistent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer</brief_title>
  <official_title>Phase II Open-Label, Multi-Center Study of CP-547, 632, an Oral Tyrosine Kinase Inhibitor of VEGFR-2, in Subjects With Recurrent or Persistent Small-Volume Epithelial Ovarian Cancer, Primary Peritoneal Serous Cancer, or Fallopian Tube Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jonsson Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: CP-547,632 may stop the growth of tumor cells by blocking the enzymes necessary&#xD;
      for their growth and by stopping blood flow to the tumor.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well CP-547,632 works in treating patients with&#xD;
      recurrent or persistent ovarian cancer, primary peritoneal cancer, or fallopian tube cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the efficacy of CP-547,632, in terms of clinical response benefit (CA 125&#xD;
           response [complete response (CR) or partial response (PR)] or stable disease ≥ 16&#xD;
           weeks), in patients with recurrent or persistent small-volume ovarian epithelial,&#xD;
           primary peritoneal serous, or fallopian tube cancer.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine progression-free survival of patients treated with this drug.&#xD;
&#xD;
        -  Determine CA 125 response (CR or PR) rate in patients treated with this drug.&#xD;
&#xD;
        -  Determine duration of CA 125 response in patients treated with this drug.&#xD;
&#xD;
        -  Determine the safety of this drug in these patients.&#xD;
&#xD;
        -  Correlate the steady state plasma concentration of this drug with efficacy and toxicity&#xD;
           in these patients.&#xD;
&#xD;
        -  Correlate clinical outcome with an angiogenic profile derived from measurement of serum&#xD;
           vascular endothelial growth factor, basic fibroblast growth factor, and interleukin-8 in&#xD;
           patients treated with this drug.&#xD;
&#xD;
        -  Determine changes in the Hospital Anxiety and Depression Scale (HADS) in patients&#xD;
           treated with this drug.&#xD;
&#xD;
      OUTLINE: This is an open-label, multicenter study.&#xD;
&#xD;
      Patients receive oral CP-547,632 once daily on days 1-28. Treatment repeats every 28 days for&#xD;
      up to 13 courses in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Patients are followed at 30 days and then every 3 months for 2 years.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 10-29 patients will be accrued for this study within 1 year.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2004</start_date>
  <completion_date type="Actual">February 2005</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <condition>Fallopian Tube Cancer</condition>
  <condition>Ovarian Cancer</condition>
  <condition>Primary Peritoneal Cavity Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CP-547,632</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed ovarian epithelial, primary peritoneal serous, or fallopian&#xD;
             tube cancer&#xD;
&#xD;
               -  Recurrent or persistent disease&#xD;
&#xD;
                    -  Elevated CA 125, defined as ≥ 40 U/mL on 2 separate consecutive measurements&#xD;
                       taken ≥ 1 week apart&#xD;
&#xD;
          -  No definitive disease OR small-volume disease (≤ 2 cm by spiral or conventional CT&#xD;
             scan or clinical exam)&#xD;
&#xD;
          -  Asymptomatic disease&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  26 and over (age 18 to 25 allowed provided there is closure of the epiphyses on&#xD;
             radiography)&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-1&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  More than 6 months&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,500/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
          -  No bleeding disorders&#xD;
&#xD;
          -  No hemorrhage ≥ grade 2 within the past 12 months&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin ≤ 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Alkaline phosphatase ≤ 2.5 times ULN&#xD;
&#xD;
          -  ALT and/or AST ≤ 2.5 times ULN&#xD;
&#xD;
          -  Albumin ≥ 3.2 g/dL&#xD;
&#xD;
          -  PT/PTT ≤ 1.5 times ULN&#xD;
&#xD;
          -  INR ≤ 1.5&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine ≤ 1.5 times ULN OR&#xD;
&#xD;
          -  Creatinine clearance ≥ 60 mL/min&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  QTc ≤ 460 msec by ECG&#xD;
&#xD;
          -  No unstable angina within the past 6 months&#xD;
&#xD;
          -  No decompensated congestive heart failure within the past 6 months&#xD;
&#xD;
          -  No myocardial infarction within the past 6 months&#xD;
&#xD;
          -  No serious cardiac arrhythmias or conduction abnormalities, including any history of&#xD;
             recurrent ventricular arrhythmia, within the past 6 months&#xD;
&#xD;
          -  No cardiomyopathy&#xD;
&#xD;
          -  No history of syncope associated with arrhythmia&#xD;
&#xD;
          -  No uncontrolled hypertension within the past 3 weeks, defined as systolic blood&#xD;
             pressure &gt; 150 mm Hg or diastolic blood pressure &gt; 90 mm Hg on ≥ 2 of 3 blood pressure&#xD;
             readings taken ≥ 5 minutes apart&#xD;
&#xD;
          -  No thrombotic cardiovascular events, including transient ischemic attacks, within the&#xD;
             past 12 months&#xD;
&#xD;
        Gastrointestinal&#xD;
&#xD;
          -  Able to take oral medication&#xD;
&#xD;
          -  No malabsorption syndromes&#xD;
&#xD;
          -  No active gastrointestinal bleeding (hematemesis, hematochezia, or melena), unrelated&#xD;
             to cancer, within the past 3 months&#xD;
&#xD;
          -  No requirement for IV alimentation&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 3 months after study&#xD;
             participation&#xD;
&#xD;
          -  No active infection&#xD;
&#xD;
          -  No uncontrolled diabetes&#xD;
&#xD;
          -  No dementia, altered mental status, or uncontrolled psychiatric illness that would&#xD;
             preclude giving informed consent or study compliance&#xD;
&#xD;
          -  No other serious uncontrolled medical disorder that would preclude study participation&#xD;
&#xD;
          -  No other active malignancy within the past 3 years except treated limited stage basal&#xD;
             cell or squamous cell skin cancer or carcinoma in situ of the breast or cervix&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  No prior exposure to mouse antibodies&#xD;
&#xD;
          -  No prior vascular endothelial growth factor (VEGF) or VEGF-receptor targeted therapy&#xD;
&#xD;
          -  No other prior antiangiogenic anticancer therapy, including thalidomide&#xD;
&#xD;
          -  No concurrent prophylactic colony-stimulating factors (i.e., filgrastim [G-CSF] or&#xD;
             sargramostim [GM-CSF])&#xD;
&#xD;
          -  No concurrent immunotherapy&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  Prior chemotherapy allowed provided patient received only a first-line platinum-based&#xD;
             chemotherapy regimen with or without systemic consolidation chemotherapy&#xD;
&#xD;
          -  At least 3 weeks since prior chemotherapy and recovered (excluding alopecia)&#xD;
&#xD;
          -  No concurrent chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  At least 3 weeks since prior hormonal therapy for ovarian cancer and recovered&#xD;
&#xD;
          -  Concurrent hormone replacement therapy allowed&#xD;
&#xD;
          -  No concurrent chronic oral or IV corticosteroids&#xD;
&#xD;
          -  No concurrent hormonal therapy, including tamoxifen&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  More than 4 weeks since prior major surgical procedure&#xD;
&#xD;
          -  No prior gastric resection&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  More than 3 weeks since prior investigational therapy&#xD;
&#xD;
          -  More than 4 weeks since prior major medical interference with the peritoneum or pleura&#xD;
&#xD;
          -  More than 3 months since prior treatment for active ulcer disease&#xD;
&#xD;
          -  No prior consolidation intraperitoneal therapy using cytotoxic agents for ovarian&#xD;
             cancer&#xD;
&#xD;
          -  No concurrent antiarrhythmics&#xD;
&#xD;
               -  Beta blockers or calcium channel blockers used for other indications allowed&#xD;
&#xD;
          -  No concurrent grapefruit juice&#xD;
&#xD;
          -  No concurrent therapeutic anticoagulant therapy or chronic daily aspirin &gt; 325 mg/day&#xD;
&#xD;
               -  Concurrent low-dose anticoagulants for maintenance of central venous access&#xD;
                  allowed&#xD;
&#xD;
          -  No other concurrent experimental or anticancer therapy for the primary disease&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark D. Pegram, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jonsson Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jonsson Comprehensive Cancer Center, UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095-1781</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2005</verification_date>
  <study_first_submitted>November 9, 2004</study_first_submitted>
  <study_first_submitted_qc>November 8, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 9, 2004</study_first_posted>
  <last_update_submitted>December 18, 2013</last_update_submitted>
  <last_update_submitted_qc>December 18, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 19, 2013</last_update_posted>
  <keyword>recurrent ovarian epithelial cancer</keyword>
  <keyword>primary peritoneal cavity cancer</keyword>
  <keyword>fallopian tube cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
    <mesh_term>Fallopian Tube Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

